Clinical Trials Logo

Leptomeningeal Neoplasm clinical trials

View clinical trials related to Leptomeningeal Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04250545 Active, not recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of CB-839 HCl when given together with sapanisertib in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). CB-839 HCl and sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03025256 Active, not recruiting - Metastatic Melanoma Clinical Trials

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Start date: May 2, 2018
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of intrathecal nivolumab, and how well it works in combination with intravenous nivolumab in treating patients with leptomeningeal disease. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.